P38MAPK/NF-Kappa B Pathway Inhibitors (Wenzhou Medical University)

N/A

Report date: 2025/01/26 15:41:15
NME

Base Information

Drug NameP38MAPK/NF-Kappa B Pathway Inhibitors (Wenzhou Medical University)
Drug Alias Namecurcumolide
ClassificationSmall moleculesNatural product/Extract
Mechanisms of ActionP38 α mitogen-activated protein kinase inhibitorsNuclear factor NF-kappa-B complex inhibitors
TargetsNuclear factor NF-kappa-B complexP38 α mitogen-activated protein kinase
Therapy Area/IndicationsDiabetic Retinopathy
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesWenzhou Medical University
China Registration ClassN/A

Develop Information

Active CompaniesWenzhou Medical University
Inactive CompaniesN/A
Active IndicationsDiabetic Retinopathy
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A